On January 2, 2013, BG Medicine, Inc. (the "Company") issued a press release announcing that the first automated version of the BGM Galectin-3® blood test has obtained a CE Mark, an important step in the Company's commercial strategy. The first automated version of the BGM Galectin-3 test will be distributed through bioMérieux's VIDAS® immunoassay platform, which includes approximately 27,000 installed instruments worldwide. bioMérieux is one of the Company's four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMérieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

(d) The following exhibit is filed with this report:

                  Exhibit
                  Number    Description

                  99.1      Press Release dated January 2, 2013.

The press release contains hypertext links to information on our website and/or other websites. The information on our website and any other website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.